OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS

口服 II 型胶原蛋白治疗幼年类风湿关节炎的开放标签研究

• 批准号: 6118900
• 负责人: DAVID TRENTHAM
• 金额: $ 2.98万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118900
• 关键词: antibody formation; antirheumatic agents; autoantibody; child (0-11); clinical research; clinical trials; collagen; human subject; human therapy evaluation; juvenile rheumatoid arthritis; oral administration; skeletal disorder chemotherapy

To test the efficacy, safety and feasibility of oral administration of type II collagen in patients with severe juvenile rheumatoid arthritis and to evaluate the effect of this treatment on collagen antibody production in those patients.

目的：探讨口服II型胶原治疗严重幼年类风湿性关节炎患者的疗效、安全性和可行性，并评价口服II型胶原治疗对该类患者胶原抗体产生的影响。